AZD5672 Bioavailability Study in Healthy Male and Female Subjects

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study-specific procedures

• BMI between 18 and 30 kg/m2

• Medical and surgical history and physical examination without any clinically significant findings

• Non smokers or past smokers who have stopped smoking within the last 6 months.

Exclusion Criteria:

• History of clinically significant cardio- or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator

• Clinically significant illness as judged by the Investigator, within two weeks before the first administration of investigational product.

• Female subjects who have a positive pregnancy test or who are pregnant or breast-feeding